Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · EUDA Health Holdings Ltd (EUDA)

EUDA Health regains Nasdaq compliance on share issue; must file late reports by Aug 4

Mixed Impact 5 of 5 legal/regulatory Written later

EUDA Health Holdings said Nasdaq told it on June 13, 2023 that it regained compliance with Listing Rule 5635(c) after CEO Dr. Kelvin Chen agreed to forfeit 271,867 of 850,306 shares issued to him in a loan settlement. Separately, Nasdaq accepted the company's plan to regain compliance with its late-filing rule, provided it files overdue reports by August 4, 2023, or faces possible delisting.

Key points

  • Chen received 850,306 restricted shares at $1.00 each to settle $850,306 in loans; the issue was priced below the $1.47 prior closing bid, which required shareholder approval.
  • Under a June 8, 2023 Supplemental Agreement, Chen forfeited 271,867 shares, leaving an effective issue price of $1.47 per share.
  • The company must file its delinquent 10-K and 10-Q by August 4, 2023; failure could lead to a delisting notice and appeal to a Nasdaq Hearings Panel.

The filing

CompanyEUDA Health Holdings Ltd (EUDA)
Form8-K, current report
Filed with the SECJun 15, 2023, 2:20 PM ET
Accession number0001493152-23-021404

Items reported: 3.01 Delisting / Listing Rule Notice8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 15, 2023.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.